MetaVia Inc.
MTVANasdaq
$1.71
↓ -5.0%Jul 17 close · end-of-day
Price
1Y↓ -76.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$8.3M
Enterprise Value
-$5.4M
P/E
—
P/S
—
P/B
0.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$13.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-144.7%
ROIC
—
Debt / Equity
—
Net Cash
$13.7M
Return 1Y
-76.8%
Company profile
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
- CEO
- Heon Kim Hyung
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 8
- Headquarters
- Massachusetts
- Website
- metaviatx.com
Management & directors
- Kim Hyung HeonCEO & President
- Woodworth Marshall HChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
MTVA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.79↓ -79.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$29.7M | -$15.3M | -$19.6M | -$15.9M | -$28.8M | -$13.7M |
| Net income | -$29.7M | -$15.3M | -$14.0M | -$12.5M | -$27.6M | -$13.0M |
| Diluted EPS | -$1.83 | -$19.81 | -$43.42 | -$2.46 | -$39.13 | -$7.35 |
| Operating cash flow | -$10.8M | -$15.1M | -$11.7M | -$10.8M | -$24.7M | -$15.7M |
| Free cash flow | -$10.8M | -$15.1M | — | -$10.8M | -$24.7M | -$15.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$10.1M | -$6.3M | -$5.6M | -$3.9M | -$4.3M | -$3.5M | -$2.0M | -$4.0M |
| Net income | -$10.1M | -$5.7M | -$5.2M | -$3.7M | -$4.0M | -$3.4M | -$1.9M | -$3.8M |
| Diluted EPS | -$1.85 | -$0.55 | -$35.41 | -$3.93 | -$0.26 | -$0.14 | -$3.02 | -$0.79 |
| Operating cash flow | -$7.3M | -$5.5M | -$5.5M | -$4.8M | -$3.1M | -$3.0M | -$4.9M | -$4.3M |
| Free cash flow | -$7.3M | -$5.5M | -$5.5M | — | — | -$3.0M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 9, 2026
Jun 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-08 | Tursi James Patrick | Award | 17,186 | $0.00 | $0.00 | filing |
| 2026-06-08 | STRICKLAND D GORDON | Award | 17,186 | $0.00 | $0.00 | filing |
| 2026-06-08 | Salsbury Michael | Award | 17,186 | $0.00 | $0.00 | filing |
| 2026-06-08 | GROVES JASON L | Award | 17,186 | $0.00 | $0.00 | filing |
| 2026-06-08 | KOVEN ANDREW I | Award | 17,186 | $0.00 | $0.00 | filing |
| 2026-06-08 | Glickman Mark A | Award | 17,186 | $0.00 | $0.00 | filing |
| 2026-01-23 | Woodworth Marshall H· Chief Financial Officer | Award | 28,000 | $0.00 | $0.00 | filing |
| 2026-01-23 | Kim Hyung Heon· CEO & President | Award | 32,000 | $0.00 | $0.00 | filing |
| 2025-08-12 | Woodworth Marshall H· Chief Financial Officer | Gift | 14,200 | $0.00 | $0.00 | filing |
| 2025-06-30 | Glickman Mark A | Award | 28,147 | $0.00 | $0.00 | filing |
| 2025-06-30 | GROVES JASON L | Award | 28,147 | $0.00 | $0.00 | filing |
| 2025-06-30 | Tursi James Patrick | Award | 28,147 | $0.00 | $0.00 | filing |
| 2025-06-30 | STRICKLAND D GORDON | Award | 28,147 | $0.00 | $0.00 | filing |
| 2025-06-30 | KOVEN ANDREW I | Award | 28,147 | $0.00 | $0.00 | filing |
| 2025-06-30 | Salsbury Michael | Award | 28,147 | $0.00 | $0.00 | filing |
Latest 15 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.